Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 41

1.

Regulation of the Natriuretic Peptide Receptor 2 (Npr2) by Phosphorylation of Juxtamembrane Serine and Threonine Residues Is Essential for Bifurcation of Sensory Axons.

Schmidt H, Dickey DM, Dumoulin A, Octave M, Robinson JW, Kühn R, Feil R, Potter LR, Rathjen FG.

J Neurosci. 2018 Nov 7;38(45):9768-9780. doi: 10.1523/JNEUROSCI.0495-18.2018. Epub 2018 Sep 24.

2.

Skeletal overgrowth-causing mutations mimic an allosterically activated conformation of guanylyl cyclase-B that is inhibited by 2,4,6,-trinitrophenyl ATP.

Dickey DM, Otto NM, Potter LR.

J Biol Chem. 2017 Jun 16;292(24):10220-10229. doi: 10.1074/jbc.M117.780536. Epub 2017 Apr 27.

3.

A Glutamate-Substituted Mutant Mimics the Phosphorylated and Active Form of Guanylyl Cyclase-A.

Otto NM, McDowell WG, Dickey DM, Potter LR.

Mol Pharmacol. 2017 Jul;92(1):67-74. doi: 10.1124/mol.116.107995. Epub 2017 Apr 17.

4.

Catalytically Active Guanylyl Cyclase B Requires Endoplasmic Reticulum-mediated Glycosylation, and Mutations That Inhibit This Process Cause Dwarfism.

Dickey DM, Edmund AB, Otto NM, Chaffee TS, Robinson JW, Potter LR.

J Biol Chem. 2016 May 20;291(21):11385-93. doi: 10.1074/jbc.M115.704015. Epub 2016 Mar 15.

5.

Special Series: A Clinical Engineer's Approach to CMS Compliance: Part Three.

Dickey DM.

Biomed Instrum Technol. 2016 Jan-Feb;50(1):48-52. doi: 10.2345/0899-8205-50.1.48. No abstract available.

PMID:
26829139
6.

Special Series: A Clinical Engineer's Approach to CMS Compliance: Part Two.

Dickey DM.

Biomed Instrum Technol. 2015 Nov-Dec;49(6):402-8. doi: 10.2345/0899-8205-49.6.402. No abstract available.

PMID:
26618835
7.

Dephosphorylation of juxtamembrane serines and threonines of the NPR2 guanylyl cyclase is required for rapid resumption of oocyte meiosis in response to luteinizing hormone.

Shuhaibar LC, Egbert JR, Edmund AB, Uliasz TF, Dickey DM, Yee SP, Potter LR, Jaffe LA.

Dev Biol. 2016 Jan 1;409(1):194-201. doi: 10.1016/j.ydbio.2015.10.025. Epub 2015 Oct 30.

8.

Special Series: A Clinical Engineer's Approach To CMS Compliance.

Dickey DM.

Biomed Instrum Technol. 2015 Sep-Oct;49(5):331-7. doi: 10.2345/0899-8205-49.5.331. No abstract available.

PMID:
26443909
9.

A human skeletal overgrowth mutation increases maximal velocity and blocks desensitization of guanylyl cyclase-B.

Robinson JW, Dickey DM, Miura K, Michigami T, Ozono K, Potter LR.

Bone. 2013 Oct;56(2):375-82. doi: 10.1016/j.bone.2013.06.024. Epub 2013 Jul 1.

10.

A functional screen provides evidence for a conserved, regulatory, juxtamembrane phosphorylation site in guanylyl cyclase a and B.

Yoder AR, Robinson JW, Dickey DM, Andersland J, Rose BA, Stone MD, Griffin TJ, Potter LR.

PLoS One. 2012;7(5):e36747. doi: 10.1371/journal.pone.0036747. Epub 2012 May 9.

11.

Guanylyl cyclase (GC)-A and GC-B activities in ventricles and cardiomyocytes from failed and non-failed human hearts: GC-A is inactive in the failed cardiomyocyte.

Dickey DM, Dries DL, Margulies KB, Potter LR.

J Mol Cell Cardiol. 2012 Mar;52(3):727-32. doi: 10.1016/j.yjmcc.2011.11.007. Epub 2011 Nov 22.

12.

ProBNP(1-108) is resistant to degradation and activates guanylyl cyclase-A with reduced potency.

Dickey DM, Potter LR.

Clin Chem. 2011 Sep;57(9):1272-8. doi: 10.1373/clinchem.2011.169151. Epub 2011 Jul 18.

13.

Antibody tracking demonstrates cell type-specific and ligand-independent internalization of guanylyl cyclase a and natriuretic peptide receptor C.

Dickey DM, Flora DR, Potter LR.

Mol Pharmacol. 2011 Jul;80(1):155-62. doi: 10.1124/mol.110.070573. Epub 2011 Apr 15. Erratum in: Mol Pharmacol. 2017 Feb;91(2):157.

14.

Benchmarking that matters: a proposed new direction for clinical engineering.

Dickey DM, Wylie M, Gresch A.

Biomed Instrum Technol. 2011 Mar-Apr;45(2):115-20. doi: 10.2345/0899-8205-45.2.115. No abstract available.

PMID:
21466328
15.

Dendroaspis natriuretic peptide and the designer natriuretic peptide, CD-NP, are resistant to proteolytic inactivation.

Dickey DM, Potter LR.

J Mol Cell Cardiol. 2011 Jul;51(1):67-71. doi: 10.1016/j.yjmcc.2011.03.013. Epub 2011 Apr 1.

16.

Insulin-degrading enzyme modulates the natriuretic peptide-mediated signaling response.

Ralat LA, Guo Q, Ren M, Funke T, Dickey DM, Potter LR, Tang WJ.

J Biol Chem. 2011 Feb 11;286(6):4670-9. doi: 10.1074/jbc.M110.173252. Epub 2010 Nov 22.

17.

Human B-type natriuretic peptide is not degraded by meprin A.

Dickey DM, Potter LR.

Biochem Pharmacol. 2010 Oct 1;80(7):1007-11. doi: 10.1016/j.bcp.2010.06.015. Epub 2010 Jun 23.

18.

Arg13 of B-type natriuretic Peptide reciprocally modulates binding to guanylyl cyclase but not clearance receptors.

Dickey DM, Barbieri KA, McGuirk CM, Potter LR.

Mol Pharmacol. 2010 Sep;78(3):431-5. doi: 10.1124/mol.110.066084. Epub 2010 Jun 8.

19.

Biodesign of a renal-protective peptide based on alternative splicing of B-type natriuretic peptide.

Pan S, Chen HH, Dickey DM, Boerrigter G, Lee C, Kleppe LS, Hall JL, Lerman A, Redfield MM, Potter LR, Burnett JC Jr, Simari RD.

Proc Natl Acad Sci U S A. 2009 Jul 7;106(27):11282-7. doi: 10.1073/pnas.0811851106. Epub 2009 Jun 18.

20.

A familial mutation renders atrial natriuretic Peptide resistant to proteolytic degradation.

Dickey DM, Yoder AR, Potter LR.

J Biol Chem. 2009 Jul 17;284(29):19196-202. doi: 10.1074/jbc.M109.010777. Epub 2009 May 19.

21.

Natriuretic peptides: their structures, receptors, physiologic functions and therapeutic applications.

Potter LR, Yoder AR, Flora DR, Antos LK, Dickey DM.

Handb Exp Pharmacol. 2009;(191):341-66. doi: 10.1007/978-3-540-68964-5_15. Review.

22.

Novel bifunctional natriuretic peptides as potential therapeutics.

Dickey DM, Burnett JC Jr, Potter LR.

J Biol Chem. 2008 Dec 12;283(50):35003-9. doi: 10.1074/jbc.M804538200. Epub 2008 Oct 21.

23.
24.

Renal hyporesponsiveness to atrial natriuretic peptide in congestive heart failure results from reduced atrial natriuretic peptide receptor concentrations.

Bryan PM, Xu X, Dickey DM, Chen Y, Potter LR.

Am J Physiol Renal Physiol. 2007 May;292(5):F1636-44. Epub 2007 Jan 30.

25.

Natriuretic peptides, their receptors, and cyclic guanosine monophosphate-dependent signaling functions.

Potter LR, Abbey-Hosch S, Dickey DM.

Endocr Rev. 2006 Feb;27(1):47-72. Epub 2005 Nov 16. Review.

PMID:
16291870
26.

Protein kinase D1 and the beta 1 integrin cytoplasmic domain control beta 1 integrin function via regulation of Rap1 activation.

Medeiros RB, Dickey DM, Chung H, Quale AC, Nagarajan LR, Billadeau DD, Shimizu Y.

Immunity. 2005 Aug;23(2):213-26.

27.

Breaking out of the biomed box: an audit assessment and recommendations for an in-house biomedical engineering program.

Dickey DM, Jagiela S, Fetters D.

Biomed Instrum Technol. 2003 Sep-Oct;37(5):329-37.

PMID:
14564804
28.

Cover your assets.

Dickey DM, Hertzler LW.

Mater Manag Health Care. 1999 Jan;8(1):24, 26-9. No abstract available.

PMID:
10351231
29.

Thio-NADP is not an antagonist of NAADP.

Dickey DM, Aarhus R, Walseth TF, Lee HC.

Cell Biochem Biophys. 1998;28(1):63-73.

PMID:
9386893
30.

Pharmacological properties of the Ca2+-release mechanism sensitive to NAADP in the sea urchin egg.

Genazzani AA, Mezna M, Dickey DM, Michelangeli F, Walseth TF, Galione A.

Br J Pharmacol. 1997 Aug;121(7):1489-95.

31.

Activation and inactivation of Ca2+ release by NAADP+.

Aarhus R, Dickey DM, Graeff RM, Gee KR, Walseth TF, Lee HC.

J Biol Chem. 1996 Apr 12;271(15):8513-6.

32.

Bilateral lung volume reduction surgery for treatment of emphysema.

Dickey DM.

AORN J. 1996 Feb;63(2):355-64, 367, 372; quiz 406, 409-14. Review.

PMID:
8907742
33.

ADP-ribosyl cyclase and CD38 catalyze the synthesis of a calcium-mobilizing metabolite from NADP.

Aarhus R, Graeff RM, Dickey DM, Walseth TF, Lee HC.

J Biol Chem. 1995 Dec 22;270(51):30327-33.

34.

Clinical engineering helps reduce equipment costs.

Dickey DM.

Healthc Financ Manage. 1995 Sep;49(9):50-3.

PMID:
10145094
35.

Preventing stagnation of a CE department.

Dickey DM.

Biomed Instrum Technol. 1993 Nov-Dec;27(6):450. No abstract available.

PMID:
8275138
36.

Telemetry for the year 2000: meeting the needs of the customer.

Dickey DM.

Biomed Instrum Technol. 1993 Sep-Oct;27(5):385-92.

PMID:
8220632
37.

New adventures in biomedical engineering: radiation safety program management.

Dickey DM.

Biomed Instrum Technol. 1991 Sep-Oct;25(5):380-4.

PMID:
1933088
38.

Surviving and growing in the '90s: managerial methods for the hospital-based BME/CE department.

Dickey DM.

Biomed Instrum Technol. 1990 Sep-Oct;24(5):345-54. No abstract available.

PMID:
2224339
39.

Clinical and microscopic pulp response to a composite restorative material.

Dickey DM, el-Kafrawy AH, Mitchell DF.

J Am Dent Assoc. 1974 Jan;88(1):108-13. No abstract available.

PMID:
4588259
40.

Pulp reaction to a polycarboxylate cement in monkeys.

el-Kafrawy AH, Dickey DM, Mitchell DF, Phillips RW.

J Dent Res. 1974 Jan-Feb;53(1):15-9. No abstract available.

PMID:
4203473
41.

Evaluation of pain of dento-alveolar origin.

Dickey DM.

Dent Clin North Am. 1973 Jul;17(3):391-402. No abstract available.

PMID:
4513762

Supplemental Content

Loading ...
Support Center